SG2918 / Sumgen Biotech - LARVOL DELTA

SG2918 For Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=17 | Completed | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Nov 2025

Trial completion • Trial completion date • Oncology • Solid Tumor

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

SG2918 For Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=17 | Active, not recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | N=117 ➔ 17

Enrollment change • Enrollment closed • Oncology • Solid Tumor

To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology

SG2918 For Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=117 | Recruiting | Sponsor: Hangzhou Sumgen Biotech Co., Ltd.

New P1 trial • Oncology • Solid Tumor